Immunotherapy Expert Dr. Brian Barnett Joins OncBioMune Scientific Advisory Board

OncBioMune Pharmaceuticals (OTCMKTS:OBMP), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that, effective immediately, Dr. Brian Barnett has joined the OncBioMune Scientific Advisory Board.
Dr. Barnett currently serves as Senior Medical Director, Neratinib, Medical Affairs at Puma Biotechnology. Prior to accepting his position at Puma Biotechnology, Dr. Barnett held numerous senior level positions at Roche Group subsidiary Genentech providing oversight in the FDA approval and launch of the potential blockbuster breast cancer drug Kadcyla. These positions at Genentech included Associate Medical Director, Kadcyla, U.S. Medical Affairs; Medical Director, Kadcyla, U.S. Medical Affairs; and Medical Director, Kadcyla, Global Product Development Oncology. Before his time at Genentech, Dr. Barnett served as Director of Medical Oncology at the Elliott, Barnett, Head Breast Cancer Research and Treatment Center.
Throughout his career, Dr. Barnett has authored and been integral to many peer-reviewed publications on immunotherapy and delivered oral and poster presentations at leading oncology conferences on regulating cancer with immunotherapy approaches.
Dr. Barnett earned a Bachelor of Science (BS) degree in Chemistry from Millsaps College, a Doctor of Medicine (MD) degree from the University of Mississippi School of Medicine and completed his medical training as a Fellow, Hematology and Medical Oncology at Tulane University Health Sciences Center. He is an active member of the American Association of Cancer Research and the American Society of Clinical Oncology.
“I’m well aware of the potential of the vaccine technology that OncBioMune is developing after working closely with Drs. Head and Elliott at their breast cancer center,” said Dr. Barnett. “I am impressed with what I see in the clinical data of ProscaVax as a novel prostate cancer vaccine and look forward to sharing my clinical experiences going forward as ProscaVax commences mid-stage studies.”
“On behalf of our entire team, I’d like to formally welcome Dr. Barnett to our Scientific Advisory Board,” said Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “Brian is highly-respected as a thought leader in the immunotherapy space and brings years of highly relevant experience to our team in Phase 2 and Phase 3 clinical research. His knowledge and network will be a invaluable assets as we move forward with not only ProscaVax, but our entire pipeline.”
Connect with Louisiana-based OncBioMune Pharmaceuticals (OTCMKTS:OBMP) to receive an Investor Presentation.